401 related articles for article (PubMed ID: 33096269)
1. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
Gaudreau PO; Negrao MV; Mitchell KG; Reuben A; Corsini EM; Li J; Karpinets TV; Wang Q; Diao L; Wang J; Federico L; Parra-Cuentas ER; Khairullah R; Behrens C; Correa AM; Gomez D; Little L; Gumbs C; Kadara HN; Fujimoto J; McGrail DJ; Vaporciyan AA; Swisher SG; Walsh G; Antonoff MB; Weissferdt A; Tran H; Roarty E; Haymaker C; Bernatchez C; Zhang J; Futreal PA; Wistuba II; Cascone T; Heymach JV; Sepesi B; Zhang J; Gibbons DL
J Thorac Oncol; 2021 Jan; 16(1):127-139. PubMed ID: 33096269
[TBL] [Abstract][Full Text] [Related]
2. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127
Hui Z; Ren Y; Zhang D; Chen Y; Yu W; Cao J; Liu L; Wang T; Xiao S; Zheng L; Pu Y; Wei F; You J; Ren X
NPJ Precis Oncol; 2023 May; 7(1):48. PubMed ID: 37231145
[TBL] [Abstract][Full Text] [Related]
4. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
6. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
7. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.
Cole KE; Ly QP; Hollingsworth MA; Cox JL; Fisher KW; Padussis JC; Foster JM; Vargas LM; Talmadge JE
Int Immunopharmacol; 2022 May; 106():108628. PubMed ID: 35203041
[TBL] [Abstract][Full Text] [Related]
8. Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.
Arbore G; Albarello L; Bucci G; Punta M; Cossu A; Fanti L; Maurizio A; Di Mauro F; Bilello V; Arrigoni G; Bonfiglio S; Biancolini D; Puccetti F; Elmore U; Vago L; Cascinu S; Tonon G; Rosati R; Casorati G; Dellabona P
Cancer Res; 2023 Sep; 83(17):2873-2888. PubMed ID: 37350667
[TBL] [Abstract][Full Text] [Related]
9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
10. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
11. Location of CD39
Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Hu J; Zhang L; Xia H; Yan Y; Zhu X; Sun F; Sun L; Li S; Li D; Wang J; Han Y; Zhang J; Bian D; Yu H; Chen Y; Fan P; Ma Q; Jiang G; Wang C; Zhang P
Genome Med; 2023 Mar; 15(1):14. PubMed ID: 36869384
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.
Feng Y; Sun W; Zhang J; Wang Y; Chen J; Liu X; Wang L; Li S; Lv C; Lu F; Zhang J; Hong Y; Xiao S; Wang T; Jiao R; Wang Z; Qi L; Li N; Yang Y; Lin D; Fang J
Thorac Cancer; 2022 Feb; 13(3):442-452. PubMed ID: 34913597
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
15. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
16. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
Xing X; Shi J; Jia Y; Dou Y; Li Z; Dong B; Guo T; Cheng X; Li X; Du H; Hu Y; Jia S; Zhang J; Li Z; Ji J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35361730
[TBL] [Abstract][Full Text] [Related]
18. Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).
Zeng A; Yin Y; Xu Z; Abuduwayiti A; Yang F; Shaik MS; Wang C; Chen K; Wang C; Fang X; Dai J
BMC Cancer; 2024 Mar; 24(1):396. PubMed ID: 38553708
[TBL] [Abstract][Full Text] [Related]
19. High post-chemotherapy TIL and increased CD4+TIL are independent prognostic factors of surgically resected NSCLC following neoadjuvant chemotherapy.
Jia W; Guo H; Wang M; Li J; Yu J; Zhu H; Wu G
MedComm (2020); 2023 Feb; 4(1):e213. PubMed ID: 36789099
[TBL] [Abstract][Full Text] [Related]
20. Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1
Liang H; Li H; Xie Z; Jin T; Chen Y; Lv Z; Tan X; Li J; Han G; He W; Qiu N; Jiang M; Zhou J; Xia H; Zhan Y; Cui L; Guo W; Huang J; Zhang X; Wu YL
Thorac Cancer; 2020 Oct; 11(10):2941-2954. PubMed ID: 32894006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
